Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.69 |
| ▸ | PPARG | P37231 | 5/20 | 0.69 |
| ▸ | F7 | P08709 | 3/20 | 0.69 |
| ▸ | F3 | P13726 | 3/20 | 0.69 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | PPARD | Q03181 | 3/20 | 0.69 |
| ▸ | PPARA | Q07869 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9463025 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL4804537 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL9463022 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL18555769 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL38661876 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL31027073 | 0.94 | ALDH1A1 (0.68) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL10599248 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL1971784 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL8856775 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP19A1PPARGF7F3 | |
| SCHEMBL8856779 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP19A1PPARGF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040089-A1 | NOVEL HETEROCYCLIC COMPOUND FOR SELECTIVELY REGULATING CANNABINOID CB1 FUNCTION | 德睿智药(苏州)新药研发有限公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-9403826-B2 | Compositions and methods for the treatment of inflammatory disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9321775-B2 | Compositions and methods for the treatment of moderate to severe pain | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9315461-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| US-9284287-B1 | Compositions and methods for the suppression of carbonic anhydrase activity | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150210667-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTONOMIC AND OTHER NEUROLOGICAL DISORDERS | KANDULA MAHESH (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150152057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-6555700-B1 | Bioactives (drugs, nutrients) in a form in which they are lipophilic so that they can pass lipid barriers (membranes, skin etc.) in the body readily; glycerides of esterified, aminated or etherified bioactives; side effect reduction | SCOTIA HOLDINGS PLC (GB) | 2003-04-29 | — | — | US | disclosed |
| EP-0942738-B1 | POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS | SCARISTA LTD (GB) | 2002-07-03 | — | — | EP | disclosed |
| US-6245811-B1 | DIFFUSION THROUGH CELL BARRIERS | SCOTIA HOLDINGS PLC (GB) | 2001-06-12 | — | — | US | disclosed |
| US-6015821-A | SKIN, PSYCHOLOGICAL AND CARDIOVASCULAR DISORDERS; ANTICARCINOGENIC, ANTIINFLAMMATORY AND ANTIDIABETIC AGENTS | SCARISTA LIMITED (IM) | 2000-01-18 | — | — | US | disclosed |
| WO-1998040059-A1 | UNSATURATED FATTY ACID ANHYDRIDES FOR USE IN THERAPY | SCOTIA HOLDINGS PLC (GB) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998013330-A1 | ESTERS OF UNSATURATED FATTY ACIDS | SCOTIA HOLDINGS PLC (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5216023-A | Antitumor agents, tyrosine kinase inhibitor | FOLLIGEN BUDAPEST LTD. (HU) | 1993-06-01 | — | — | US | disclosed |
| EP-0161422-B1 | ALKANOLAMINE DERIVATIVES AND PLATELET AGGREGATION INHIBITORS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4619938-A | Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors | TERUMO KABUSHIKI KAISHA (JP) | 1986-10-28 | — | — | US | disclosed |
| EP-0161422-A1 | Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 436/4885CYP19A1 693/4885PPARG 405/4885 |
| US-20150152057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | MAPT, TARDBP, SLC6A11 | ALDH1A1 1182/4885CYP19A1 924/4885PPARG 1663/4885 |
| US-20150210667-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTONOMIC AND OTHER NEUROLOGICAL DISORDERS | FH, FAH, FAP | ALDH1A1 750/4885CYP19A1 3133/4885PPARG 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.